A recent study revealed that IL4I1 expression was enhanced in most tumor entities compared with that of normal tissues, and IL4I1 is a metabolic immune checkpoint, thereby suppressing adaptive immune responses and promoting chronic lymphocytic leukemia progression (Sadik et al., 2020). The gene discussed is IL4I1; the disease is neoplasm.